Topline Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments. Get Forbes Breaking News Text Alerts: We're launching text message alerts so you'll always know the biggest stories shaping the day's headlines. Text "Alerts" to (201) 335-0739 or sign up here. Contra Hims announced ...